ASC's therapy uses CRISPR-Cas9 editing to insert a healthy copy of the FVIII gene into cells so that a working clotting factor might enter the blood.
2 Comments
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed